Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Protocol No

WEILLCORNELL-AMY2006-DPD

Phase

II

Summary

The purpose of this study is to assess the tolerability and safety of an investigational combination of drugs in relapsed/refractory AL amyloidosis.

Description

DPd in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL